Evidence map›Paper›PMID 22606244›Full record

ArticlePloS one2012

Suppression of ribosomal function triggers innate immune signaling through activation of the NLRP3 inflammasome.

Meghan L Vyleta, John Wong, Bruce E Magun

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 53 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Mechanistic basis for potassium efflux-driven activation of the human NLRP1 inflammasome.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  6. Article
  7. The NLRP3 inflammasome: activation and regulation.Trends in biochemical sciences · 2023
    Review
  8. Organellar homeostasis and innate immune sensing.Nature reviews. Immunology · 2022
    Review
  9. Article
  10. Article
  11. Identification of Diagnostic Gene Markers and Immune Infiltration in Systemic Lupus.Computational and mathematical methods in medicine · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Meghan L VyletaDepartment of Cell and Developmental Biology, Oregon Health and Science University, Portland, Oregon, United States of America.
John Wong
Bruce E Magun
Oregon Health & Science University · US

Funding

Program in Molecular and Cellular BiosciencesT32GM071338 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI MASLEN, CHERYL L · 2005 to 2020
$3.5M
Structure-function of Junin virus envelope glycoproteinsR21AI059355 · NIAID · UNIVERSITY OF MONTANA · PI NUNBERG, JACK H · 2004 to 2005
$491k
NIAID NIH HHS AI059355NIAID NIH HHS R21 AI059355NIGMS NIH HHS GM071338NIGMS NIH HHS T32 GM071338
6 · The paper itself

Abstract

Some inflammatory stimuli trigger activation of the NLRP3 inflammasome by inducing efflux of cellular potassium. Loss of cellular potassium is known to potently suppress protein synthesis, leading us to test whether the inhibition of protein synthesis itself serves as an activating signal for the NLRP3 inflammasome. Murine bone marrow-derived macrophages, either primed by LPS or unprimed, were exposed to a panel of inhibitors of ribosomal function: ricin, cycloheximide, puromycin, pactamycin, and anisomycin. Macrophages were also exposed to nigericin, ATP, monosodium urate (MSU), and poly I:C. Synthesis of pro-IL-ß and release of IL-1ß from cells in response to these agents was detected by immunoblotting and ELISA. Release of intracellular potassium was measured by mass spectrometry. Inhibition of translation by each of the tested translation inhibitors led to processing of IL-1ß, which was released from cells. Processing and release of IL-1ß was reduced or absent from cells deficient in NLRP3, ASC, or caspase-1, demonstrating the role of the NLRP3 inflammasome. Despite the inability of these inhibitors to trigger efflux of intracellular potassium, the addition of high extracellular potassium suppressed activation of the NLRP3 inflammasome. MSU and double-stranded RNA, which are known to activate the NLRP3 inflammasome, also substantially inhibited protein translation, supporting a close association between inhibition of translation and inflammasome activation. These data demonstrate that translational inhibition itself constitutes a heretofore-unrecognized mechanism underlying IL-1ß dependent inflammatory signaling and that other physical, chemical, or pathogen-associated agents that impair translation may lead to IL-1ß-dependent inflammation through activation of the NLRP3 inflammasome. For agents that inhibit translation through decreased cellular potassium, the application of high extracellular potassium restores protein translation and suppresses activation of the NLRP inflammasome. For agents that inhibit translation through mechanisms that do not involve loss of potassium, high extracellular potassium suppresses IL-1ß processing through a mechanism that remains undefined.

Indexed as

AnimalsCarrier ProteinsImmunity, InnateInflammasomesInterleukin-1betaIn Vitro TechniquesIon TransportLeupeptinsMacrophagesMaleMiceMice, Inbred C57BLMice, KnockoutModels, BiologicalNLR Family, Pyrin Domain-Containing 3 ProteinPotassiumbenzyloxycarbonylleucyl-leucyl-leucine aldehydeCarrier ProteinsInflammasomesInterleukin-1betaLeupeptinsNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mousePotassiumProteasome InhibitorsRNA, Double-StrandedUric Acid

Identifiers

PMID22606244
PMCPMC3351443
OpenAlexW2027560498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.